Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Serious invasive infections caused by multidrug-resistant Staphylococcus aureus (MRSA) have limited established treatment options.
• Vancomycin is the current gold standard, but increasing in vitro resistance and clinical failures highlight the urgent need for alternative therapies.
• The rise of community-acquired MRSA necessitates reevaluation of existing and novel treatment strategies.

Purpose of the Study:

• To review current and emerging therapeutic options for invasive infections caused by multidrug-resistant Staphylococcus aureus (MRSA).
• To discuss the limitations of vancomycin and the rationale for exploring alternative treatments.
• To highlight newer agents and combination therapy approaches for refractory MRSA infections.

Main Methods:

• Literature review of established and investigational treatments for MRSA infections.
• Analysis of in vitro activity, clinical data, and administration routes for various antistaphylococcal agents.
• Consideration of combination therapy for complex and refractory cases.

Main Results:

• Older agents like trimethoprim-sulfamethoxazole and clindamycin show favorable in vitro activity but have limited clinical data for invasive disease.
• Newer agents including linezolid, quinupristin-dalfopristin, daptomycin, and tigecycline offer alternatives, mostly requiring intravenous administration.
• Combination therapy may be beneficial for severe infections like endocarditis, meningitis, and prosthetic device infections.
• Several novel agents like oritavancin, dalbavancin, telavancin, and ceftobiprole are in late-stage clinical development.

Conclusions:

• The increasing challenge of MRSA necessitates a broader therapeutic armamentarium beyond vancomycin.
• Older agents and newer intravenous drugs represent important options, with ongoing research into novel agents and combination strategies.
• Effective management of invasive MRSA infections requires careful consideration of drug resistance patterns, patient factors, and infection site.